Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2

CT-322 is a new anti-angiogenic therapeutic agent based on an engineered variant of the tenth type III domain of human fibronectin, i.e., an Adnectin™, designed to inhibit vascular endothelial growth factor receptor (VEGFR)-2. This PE Gylated Adnectin was developed using an mRNA display technology....

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Mamluk, Roni, Carvajal, Irvith M, Morse, Brent A, Wong, Henry, Abramowitz, Janette, Aslanian, Sharon, Lim, Ai-Ching, Gokemeijer, Jochem, Storek, Michael J, Lee, Joonsoo, Gosselin, Michael, Wright, Martin C, Camphausen, Ray T, Wang, Jack, Chen, Yan, Miller, Kathy, Sanders, Kerry, Short, Sarah, Sperinde, Jeff, prasad, Gargi, Williams, Stephen, Kerbel, Robert, ebos, John, Mutsaers, Anthony, Mendlein, John D, Harris, Alan S, Furfine, Eric S
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Landes Bioscience 2010
Θέματα:
Reports
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2840239/
https://ncbi.nlm.nih.gov/pubmed/20190562
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια